Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a 'Buy' rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $66 to $65.
August 07, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia Therapeutics' price target has been lowered from $66 to $65 by Canaccord Genuity, though the 'Buy' rating is maintained.
The news is directly about Intellia Therapeutics. The lowering of the price target might have a slight negative impact on the stock price in the short term. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the stock, which could balance out the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100